Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

LRRK2 inhibitor progresses for Parkinson disease

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Nature Reviews Drug Discovery 21, 558 (2022)

doi: https://doi.org/10.1038/d41573-022-00121-2

References

  1. Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.abj265 (2022)

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links